Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Change in Receivables: 2012-2025

Historic Change in Receivables for Veracyte (VCYT) over the last 13 years, with Sep 2025 value amounting to -$425,000.

  • Veracyte's Change in Receivables rose 74.85% to -$425,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 79.62%. This contributed to the annual value of $6.4 million for FY2024, which is 264.78% up from last year.
  • Veracyte's Change in Receivables amounted to -$425,000 in Q3 2025, which was up 84.66% from -$2.8 million recorded in Q2 2025.
  • Veracyte's 5-year Change in Receivables high stood at $7.1 million for Q1 2025, and its period low was -$3.1 million during Q2 2023.
  • Its 3-year average for Change in Receivables is $579,636, with a median of -$425,000 in 2025.
  • As far as peak fluctuations go, Veracyte's Change in Receivables soared by 1,674.79% in 2021, and later tumbled by 383.72% in 2023.
  • Quarterly analysis of 5 years shows Veracyte's Change in Receivables stood at $2.3 million in 2021, then plummeted by 93.92% to $139,000 in 2022, then skyrocketed by 448.92% to $763,000 in 2023, then slumped by 360.94% to -$2.0 million in 2024, then spiked by 74.85% to -$425,000 in 2025.
  • Its last three reported values are -$425,000 in Q3 2025, -$2.8 million for Q2 2025, and $7.1 million during Q1 2025.